Lucknow Speciality Pharma

Acalabrutinib Capsules 100 mg
Acalabrutinib is used to treat mantle cell lymphoma (MCL) in adults who have received at least one previous treatment for their cancer. This medicine is also used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). To get access, please contact Patient Support Team @ +91 9760014849 / 9555306364 / 9794360370 / 9140551027, Time 9 am - 8 pm IST or send us a request on email (urgent@lucknowpharma.com) / WhatsApp for the same.

Acalabrutinib Capsules was approved for medical use in the United States in 2017. It is on the World Health Organization’s List of Essential Medicines.

Acalabrutinib Capsules Available Price In Lucknow Banaras Nepal

Acalabrutinib Capsules

  • Generic Brand Available – CALQUENCE
  • API – Acalabrutinib
  • Packaging – 60 Capsules
  • Strength – 100 mg

What is Acalabrutinib Capsules used for?

Acalabrutinib Capsules is used to treat mantle cell lymphoma (MCL) in adults who have received at least one previous treatment for their cancer. This medicine is also used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

About Us

Lucknow Speciality Pharma is dedicated to delivering life-changing healthcare solutions. As a trusted wholesale supplier of specialized medicines, we cater to critical care areas such as oncology, nephrology, and rare diseases. Our patient-centric approach also includes personalized catering services, ensuring that patients receive the care, support, and nutrition they need to thrive. We also extend our services globally, welcoming international patients and buyers who seek our expertise and high-quality products.

Lucknow Speciality Pharma is a registered Pharmaceutical Firm in Lucknow, India. Registered under GST Act. Registration Number : 09AAOPG3102HIZY. It provide assistance and connectivity with drug pharmacies or distributors for access to genuine medicines at competitive prices. 

Get Access To Acalabrutinib Capsules 100 mg

Enter Buying Requirements Details

For precise quotations, kindly ensure your requirements include the product name, order quantity, intended usage, and any special requests you may have.

Branch Offices in India : Lucknow | Agra | Varanasi | Gorakhpur | Kanpur | Indore | Patna | Kolkata | Nepal

FAQs – Medicine Questions

Acalabrutinib Capsules 100 mg
Is acalabrutinib a pill?
Acalabrutinib comes as a capsule to take by mouth. It is usually taken with or without food every 12 hours (twice a day) for as long as your doctor recommends that you receive treatment. Take acalabrutinib at around the same times every day.
How is acalabrutinib administered?

Administer CALQUENCE prior to obinutuzumab when given on the same day. Advise patients to swallow capsule whole with water. Advise patients not to open, break or chew the capsules. CALQUENCE may be taken with or without food.

Is acalabrutinib available in the UK?

Acalabrutinib approved for NHS treatment of CLL in England and Wales. NICE has approved acalabrutinib for NHS use for some people with CLL

Where can I buy Acalabrutinib Capsules?

You can buy Acalabrutinib Capsules from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

The buyer should check the existing law in their home country before importing the product.

What is the procedure to buy Acalabrutinib Capsules?

Patients can simply fill the order form or can send mail at info@lucknowpharma.com  Patients can also send WhatsApp messages to +91-9555306364 We will reply ASAP with the details of the Acalabrutinib Capsules price as well as procurement procedure.

Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

How long do you take CALQUENCE?
CALQUENCE is a 100-mg capsule taken by mouth, twice a day, about every 12 hours.

NEWS / UPDATES

  1. AstraZeneca, Electronica medicines compendium (emc), [ Revised on Dec 2020], [ Accessed on April 2021],  https://www.medicines.org.uk/emc/files/pil.11917.pdf
  2. AstraZeneca, US Food and Drug Administration, [ Revised on Oct 2017], [ Accessed on April 2021],  https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf
  3. John C Byrd et al; Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results; Blood; Published on April 2020; Accessed on 01/12/2021;  https://pubmed.ncbi.nlm.nih.gov/31876911/